NYSEAMERICAN:CRMD - CorMedix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.62 -0.03 (-1.82 %) (As of 12/9/2018 04:00 PM ET)Previous Close$1.62Today's Range$1.50 - $1.846352-Week Range$0.17 - $2.40Volume6.96 million shsAverage Volume2.78 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey. Receive CRMD News and Ratings via Email Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:CRMD Previous SymbolNYSEMKT:CRMD CUSIPN/A Webwww.cormedix.com Phone+1-908-5179500 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees14 Outstanding Shares105,310,000Market Cap$0.00 OptionableOptionable CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions What is CorMedix's stock symbol? CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD." How were CorMedix's earnings last quarter? CorMedix Inc. (NYSEAMERICAN:CRMD) released its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.10). The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.10 million. View CorMedix's Earnings History. When is CorMedix's next earnings date? CorMedix is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for CorMedix. What price target have analysts set for CRMD? 2 Wall Street analysts have issued 1-year price objectives for CorMedix's stock. Their forecasts range from $3.00 to $6.00. On average, they expect CorMedix's share price to reach $4.50 in the next year. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Price Targets for CorMedix. What is the consensus analysts' recommendation for CorMedix? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix. Has CorMedix been receiving favorable news coverage? Media stories about CRMD stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CorMedix earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. Are investors shorting CorMedix? CorMedix saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 12,351,937 shares, an increase of 7.4% from the October 31st total of 11,503,123 shares. Based on an average trading volume of 2,657,645 shares, the days-to-cover ratio is presently 4.6 days. Currently, 13.1% of the shares of the stock are short sold. View CorMedix's Current Options Chain. Who are some of CorMedix's key competitors? Some companies that are related to CorMedix include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE). Who are CorMedix's key executives? CorMedix's management team includes the folowing people: Mr. Khoso Baluch, CEO & Director (Age 60)Mr. Robert W. Cook, Chief Financial Officer (Age 62)Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 74)Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 39)Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance Who are CorMedix's major shareholders? CorMedix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.54%), EAM Investors LLC (0.72%), Virtu Financial LLC (0.39%) and Franklin Resources Inc. (0.17%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Institutional Ownership Trends for CorMedix. Which major investors are selling CorMedix stock? CRMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc.. View Insider Buying and Selling for CorMedix. Which major investors are buying CorMedix stock? CRMD stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., EAM Investors LLC and Virtu Financial LLC. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix. How do I buy shares of CorMedix? Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CorMedix's stock price today? One share of CRMD stock can currently be purchased for approximately $1.62. What is CorMedix's official website? The official website for CorMedix is http://www.cormedix.com. How can I contact CorMedix? CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500. MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 203 (Vote Outperform)Underperform Votes: 208 (Vote Underperform)Total Votes: 411MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/9/2018 by MarketBeat.com StaffFeatured Article: Why do company’s buyback their stock?